Dr. Patrick O'Donoghue is an Assistant Professor in the Departments of Chemistry and Biochemistry at the University of Western Ontario as well as a Tier 2 Canada Research Chair in Chemical Biology. He is currently researching non-canonical amino acids and the role of mis-modified proteins in oncogenesis.
Dr. O'Donoghue grew up in the Chicago region and graduated from the University of Illinois with a focus in biophysics before obtaining a Ph.D. in Chemistry at said university. He completed his graduate and postdoctoral fellowship at the University of Illinois before joining Professor Dieter Söll at Yale University to work in biophysics and biochemistry.
Dr. O'Donoghue started his current research path while in graduate school as he worked on the computation problem regarding protein folding and electronically predicting their structure based on known sequences. While it is possible to determine the shape experimentally, the process was and continues to be expensive. As scientists turned to computational prediction methods as an alternative, they quickly found that such methods were not as simple as they believed. The team that Dr. O'Donoghue worked with discovered that it it is possible to greatly change the protein sequence without altering the protein structure. Thus many sequences are able to form the same protein structure, making it far harder to predict protein structure than expected.
The team's research revealed that in relation to protein shapes, protein structures are conserved for a much greater timeframe than sequences. As a result, they started making phylogenetic trees from protein structure. The first tree they made was for the protein tRNA synthetase, the enzymes that put the amino acids on tRNAs and are responsible for establishing the genetic code. This research eventually led Dr. O'Donoghue to molecular evolution and the construction of history of life based on the comparison of first sequences. Currently, Dr. O'Donoghue's lab is engineering the genetic code. They reassign the stop codon UAG to instead encode an amino acid called phosphoserine, which is a post-translational modification that is normally used to transmit cellular signals. Seeing as these modifications are often over-abundant in cancer cells, there is a desire to understand the molecular function of specific phosphorylation. There is also a desire to use to the tools currently available to produce active human kinases (enzyme that catalyze the transfer of a phosphate group) for the purpose of drug screening. Dr. O'Donoghue's lab is able to engineer E. coli to produce proteins with site-specific post-translational modifications and observe how different proteins stimulate different functions.
One of the kinases currently being researched is AKT1, an oncogenic kinase that will turn the cell into a cancer cell should it become active. In a cell there can be numerous kinases that interact with different parts of the molecule and each other; it is believed that these interactions control the signaling between cells. If AKT1 becomes hyperactive the cell would turn into a cancerous cell. By developing molecular-detailed map of the signaling pathway, it may possible to find specific inhibitors and stop the kinases from becoming active.
The receptor tyrosine kinases initiate phosphorylation cascades that lead to changes in gene transcription. There are phosphorylations that ultimately lead to AKT1 activation. When AKT1 is active, transcription of apoptosis is shut down and genes that make the cell proliferate are turned on, both processes that help cancer cells grow out of control. Normally an extensive process involving three upstream kinases a mixture of lipid soluble compounds is required to synthesize the active AKT1. However, Dr. O'Donoghue's lab has been able to develop a method that allows direct production of pure active AKT1.
While some of the kinase pathways are known there are still many whose effects are unknown. Using the data collected from mass spectrometry, it is possible to determine various phosphorylation sites. Combined with the technique used by Dr. O'Donoghue it has become possible to test the function of various unknown phosphorylation sites. The medical application of this research comes down to the ability to synthesize drug targets that can then be used to find inhibitors for certain pathways and thus stop oncogenic kinases from becoming active 
